8月5日，银休特盘中下跌23.5%，报128.14美元/股，成交额5773.57万美元。
消息面上，公司于当日盘前发布第二季度财报。实际业绩显著超出市场预期：调整后每股收益1.66美元，超预期14.48%，同比增长41.88%；营收8.017亿美元，超市场一致预期的7.87亿美元。然而，公司同步下调全年营收指引，市场对增长前景的担忧压倒了短期业绩利好，引发大幅抛售。
此外，公司此前因制造缺陷对部分Omnipod产品发起自愿医疗器械纠正，FDA亦就其胰岛素泵发布潜在高风险早期预警，监管压力持续悬于估值之上。财报前已有多家机构下调目标价，UBS更将评级从买入降至中性，目标价由400美元大幅调降至174美元。
银休特主要从事Omnipod胰岛素持续递送系统的开发、制造和销售，服务于胰岛素依赖型糖尿病患者。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.